Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$192.04
+0.5%
$175.21
$111.09
$199.99
$11.74B0.41496,593 shs383,694 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$26.69
-0.7%
$29.18
$23.15
$91.99
$10.38B1.8310.81 million shs5.79 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$48.95
-0.6%
$48.22
$37.63
$51.88
$10.88B0.641.38 million shs841,447 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-2.50%+4.64%+9.26%+21.29%+36.82%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Moderna, Inc. stock logo
MRNA
Moderna
+4.79%+0.67%-18.19%+13.70%-67.56%
Qiagen N.V. stock logo
QGEN
Qiagen
+0.55%+3.75%+2.07%+16.73%+10.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.2162 of 5 stars
4.51.00.00.03.21.70.6
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
4.4478 of 5 stars
4.02.00.04.62.32.50.6
Qiagen N.V. stock logo
QGEN
Qiagen
3.5074 of 5 stars
1.12.01.74.52.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$242.9326.50% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5963.31% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.27
Hold$49.691.50% Upside

Current Analyst Ratings Breakdown

Latest MOR, QGEN, MRNA, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$243.00 ➝ $290.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$210.00 ➝ $230.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$306.00 ➝ $307.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$212.00 ➝ $254.00
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M29.84N/AN/A($3.48) per share-55.18
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.21N/AN/A$24.16 per share1.10
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.50$3.20 per share15.28$15.77 per share3.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$5.16N/A800.17N/A-54.94%N/A-24.31%N/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%N/A
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$1.6928.9219.902.5718.30%14.77%8.87%N/A

Latest MOR, QGEN, MRNA, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.51%N/A14.79%N/A

Latest MOR, QGEN, MRNA, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.02
0.69
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Qiagen N.V. stock logo
QGEN
Qiagen
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

Qiagen N.V. (NYSE:QGEN) Shares Purchased by Forsta AP Fonden
William Blair Forecasts Qiagen's Q2 Earnings (NYSE:QGEN)
QIAGEN (NYSE:QGEN) Downgraded by Wall Street Zen to "Buy"
Qiagen (NYSE:QGEN) Cut to Buy at Wall Street Zen
Qiagen (NYSE:QGEN) Issues FY 2025 Earnings Guidance
Qiagen (NYSE:QGEN) Issues Q3 2025 Earnings Guidance
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
A Look at Qiagen's Upcoming Earnings Report

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$192.04 +0.96 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$192.04 0.00 (0.00%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 08/13/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.69 -0.20 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$26.68 -0.02 (-0.06%)
As of 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Qiagen stock logo

Qiagen NYSE:QGEN

$48.95 -0.28 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$48.95 0.00 (-0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.